GEIS 2013 guidelines for gastrointestinal sarcomas (GIST) Andrés PovedaXavier García del MuroJavier Martín-Broto Review Article Open access 06 September 2014 Pages: 883 - 898
Importance of branched-chain amino acids in patients with liver cirrhosis and advanced hepatocellular carcinoma receiving hepatic arterial infusion chemotherapy Takenori KanekawaHidenari NagaiYasukiyo Sumino Original Article 20 August 2014 Pages: 899 - 909
A phase I trial of gemcitabine, S-1 and LV combination (GSL) therapy in advanced pancreatic cancer Yousuke NakaiHiroyuki IsayamaKazuhiko Koike Original Article 21 August 2014 Pages: 911 - 915
A phase I dose-escalation study of MEDI-575, a PDGFRα monoclonal antibody, in adults with advanced solid tumors Carlos R. BecerraPaul ConklingNaimish Pandya Original Article Open access 23 August 2014 Pages: 917 - 925
Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103) Jan H. BeumerKouros OwzarMerrill J. Egorin Original Article 28 August 2014 Pages: 927 - 938
Evaluation of gefitinib efficacy according to body surface area in patients with non-small cell lung cancer harboring an EGFR mutation Satoshi IgawaMasashi KasajimaNoriyuki Masuda Original Article 31 August 2014 Pages: 939 - 946
TACE plus sorafenib for the treatment of hepatocellular carcinoma: results of the multicenter, phase II SOCRATES trial Andreas ErhardtFrank KolligsDieter Häussinger Original Article 31 August 2014 Pages: 947 - 954
A phase I and pharmacokinetic study of oral perifosine with different loading schedules in patients with refractory neoplasms William D. FiggManish MongaEdward A. Sausville Original Article 03 September 2014 Pages: 955 - 967
Mechanistic pharmacokinetic/pharmacodynamic modeling of in vivo tumor uptake, catabolism, and tumor response of trastuzumab maytansinoid conjugates Russ WadaHans K. EricksonJay Tibbitts Original Article 04 September 2014 Pages: 969 - 980
Expression of a novel peptide derived from PCNA damages DNA and reverses cisplatin resistance Robert G. LingemanRobert J. HickeyLinda H. Malkas Original Article 05 September 2014 Pages: 981 - 993
Non-surgical treatment versus radical esophagectomy for clinical T1N0M0 esophageal carcinoma: a single-center experience Inkeun ParkYong-Hee KimSung-Bae Kim Original Article 05 September 2014 Pages: 995 - 1003
Effectiveness and safety of cabazitaxel plus prednisolone chemotherapy for metastatic castration-resistant prostatic carcinoma: data on Korean patients obtained by the cabazitaxel compassionate-use program Jae-Lyun LeeSe Hoon ParkHo Yeong Lim Original Article 06 September 2014 Pages: 1005 - 1013
Heat shock protein 90 (HSP90) is overexpressed in p16-negative oropharyngeal squamous cell carcinoma, and its inhibition in vitro potentiates the effects of chemoradiation Kirtesh PatelJing WenRoberto Diaz Original Article 10 September 2014 Pages: 1015 - 1022
Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases Tatsushi KodamaMasami HasegawaHiroshi Sakamoto Original Article 10 September 2014 Pages: 1023 - 1028
Leucovorin rescue allows effective high-dose pralatrexate treatment and an increase in therapeutic index in mesothelioma xenografts Philip M. TedeschiYamini K. KathariJoseph R. Bertino Original Article Open access 09 September 2014 Pages: 1029 - 1032
Prognostic value of human papillomavirus in anal squamous cell carcinoma Paola Simona RavendaElena MagniMaria Giulia Zampino Original Article 11 September 2014 Pages: 1033 - 1038
A first-in-human study of the anti-α5β1 integrin monoclonal antibody PF-04605412 administered intravenously to patients with advanced solid tumors J. MateoJ. BerlinH. Borghaei Original Article Open access 12 September 2014 Pages: 1039 - 1046
Pharmacokinetics of the chimeric anti-GD2 antibody, ch14.18, in children with high-risk neuroblastoma Ami V. DesaiElizabeth FoxFrank M. Balis Original Article 12 September 2014 Pages: 1047 - 1055
Clinical study of the novel cyclin-dependent kinase inhibitor dinaciclib in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia patients Claire FabreMarco GobbiChristophe Le Tourneau Original Article 13 September 2014 Pages: 1057 - 1064
Significant association of combination of OCT4, NANOG, and SOX2 gene polymorphisms in susceptibility and response to treatment in North Indian breast cancer patients Sonam TulsyanGaurav AgarwalBalraj Mittal Original Article 16 September 2014 Pages: 1065 - 1078
Phase I trial of hepatic arterial infusion (HAI) of floxuridine with modified oxaliplatin, 5-fluorouracil and leucovorin (m-FOLFOX6) in Chinese patients with unresectable liver metastases from colorectal cancer Cong LiYangkui GuYuhong Li Clinical Trial Report 13 September 2014 Pages: 1079 - 1087
A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and various degrees of hepatic function Marije SlingerlandDagmar HessHans Gelderblom Clinical Trial Report 25 September 2014 Pages: 1089 - 1098
Predicting success in regulatory approval from Phase I results Laeeq MalikAlex MejiaSteven Weitman Short Communication 23 September 2014 Pages: 1099 - 1103